Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

(2010) Jia Ruan et al.   JOURNAL OF CLINICAL ONCOLOGY

Model calibration in the continual reassessment method

(2009) Shing M Lee et al.   Clinical Trials

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

A comparison of model choices for the continual reassessment method in phase I cancer trials

(2009) X. Paoletti et al.   STATISTICS IN MEDICINE

The Neuroprotection with Statin Therapy for Acute Recovery Trial (Neustart): An Adaptive Design Phase I Dose-Escalation Study of High-Dose Lovastatin in Acute Ischemic Stroke

(2008) Mitchell S. V. Elkind et al.   International Journal of Stroke

Unifying CRM and EWOC designs for phase I cancer clinical trials

(2008) Pei-Ling Chu et al.   JOURNAL OF STATISTICAL PLANNING AND INFERENCE